Literature DB >> 33615743

Environment-Responsive Lipid/siRNA Nanoparticles for Cancer Therapy.

Zheng-Rong Lu1, Victoria E A Laney1, Ryan Hall1, Nadia Ayat1.   

Abstract

RNA interference (RNAi) is a promising technology to regulate oncogenes for treating cancer. The primary limitation of siRNA for clinical application is the safe and efficacious delivery of therapeutic siRNA into target cells. Lipid-based delivery systems are developed to protect siRNA during the delivery process and to facilitate intracellular uptake. There is a significant progress in lipid nanoparticle systems that utilize cationic and protonatable amino lipid systems to deliver siRNA to tumors. Among these lipids, environment-responsive lipids are a class of novel lipid delivery systems that are capable of responding to the environment changes during the delivery process and demonstrate great promise for clinical translation for siRNA therapeutics. Protonatable or ionizable amino lipids and switchable lipids as well as pH-sensitive multifunctional amino lipids are the presentative environment-responsive lipids for siRNA delivery. These lipids are able to respond to environmental changes during the delivery process to facilitate efficient cytosolic siRNA delivery. Environment-responsive lipid/siRNA nanoparticles (ERLNP) are developed with the lipids and are tested for efficient delivery of therapeutic siRNA into the cytoplasm of cancer cells to silence target genes for cancer treatment in preclinical development. This review summarizes the recent developments in environment-response lipids and nanoparticles for siRNA delivery in cancer therapy.
© 2020 Wiley-VCH GmbH.

Entities:  

Keywords:  cancer therapy; environment-responsive lipids; nanoparticles; siRNA; siRNA delivery

Mesh:

Substances:

Year:  2020        PMID: 33615743     DOI: 10.1002/adhm.202001294

Source DB:  PubMed          Journal:  Adv Healthc Mater        ISSN: 2192-2640            Impact factor:   9.933


  5 in total

1.  Regulating Oncogenic LncRNA DANCR with Targeted ECO/siRNA Nanoparticles for Non-Small Cell Lung Cancer Therapy.

Authors:  Calin Nicolescu; Amita Vaidya; Andrew Schilb; Zheng-Rong Lu
Journal:  ACS Omega       Date:  2022-06-17

Review 2.  Emerging role of exosomes in cancer progression and tumor microenvironment remodeling.

Authors:  Mahshid Deldar Abad Paskeh; Maliheh Entezari; Sepideh Mirzaei; Amirhossein Zabolian; Hossein Saleki; Mohamad Javad Naghdi; Sina Sabet; Mohammad Amin Khoshbakht; Mehrdad Hashemi; Kiavash Hushmandi; Gautam Sethi; Ali Zarrabi; Alan Prem Kumar; Shing Cheng Tan; Marios Papadakis; Athanasios Alexiou; Md Asiful Islam; Ebrahim Mostafavi; Milad Ashrafizadeh
Journal:  J Hematol Oncol       Date:  2022-06-28       Impact factor: 23.168

3.  Ambient synthesis of an iminium-linked covalent organic framework for synergetic RNA interference and metabolic therapy of fibrosarcoma.

Authors:  Le-Le Zhou; Qun Guan; Wei Zhou; Jing-Lan Kan; Yu-Bin Dong
Journal:  Chem Sci       Date:  2022-06-15       Impact factor: 9.969

Review 4.  Genetic Variants in Transcription Factor Binding Sites in Humans: Triggered by Natural Selection and Triggers of Diseases.

Authors:  Chia-Chun Tseng; Man-Chun Wong; Wei-Ting Liao; Chung-Jen Chen; Su-Chen Lee; Jeng-Hsien Yen; Shun-Jen Chang
Journal:  Int J Mol Sci       Date:  2021-04-18       Impact factor: 5.923

Review 5.  Recent advances in redox-responsive nanoparticles for combined cancer therapy.

Authors:  Yanjun Yang; Wen Sun
Journal:  Nanoscale Adv       Date:  2022-07-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.